CN100509055C - 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 - Google Patents

使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 Download PDF

Info

Publication number
CN100509055C
CN100509055C CNB028185722A CN02818572A CN100509055C CN 100509055 C CN100509055 C CN 100509055C CN B028185722 A CNB028185722 A CN B028185722A CN 02818572 A CN02818572 A CN 02818572A CN 100509055 C CN100509055 C CN 100509055C
Authority
CN
China
Prior art keywords
gly
amino acid
group
thrombin
healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028185722A
Other languages
English (en)
Chinese (zh)
Other versions
CN1556711A (zh
Inventor
达芮尔·H·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capstone Holding Corp
Original Assignee
Osorogis Ltd
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osorogis Ltd, The University of Texas System filed Critical Osorogis Ltd
Publication of CN1556711A publication Critical patent/CN1556711A/zh
Application granted granted Critical
Publication of CN100509055C publication Critical patent/CN100509055C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB028185722A 2001-07-27 2002-01-16 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 Expired - Fee Related CN100509055C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30819801P 2001-07-27 2001-07-27
US60/308,198 2001-07-27

Publications (2)

Publication Number Publication Date
CN1556711A CN1556711A (zh) 2004-12-22
CN100509055C true CN100509055C (zh) 2009-07-08

Family

ID=23192964

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028185722A Expired - Fee Related CN100509055C (zh) 2001-07-27 2002-01-16 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡

Country Status (11)

Country Link
US (3) US7049294B2 (enExample)
EP (1) EP1414487B1 (enExample)
JP (1) JP4192093B2 (enExample)
CN (1) CN100509055C (enExample)
AT (1) ATE328606T1 (enExample)
AU (1) AU2002236768B2 (enExample)
CA (1) CA2455756C (enExample)
DE (1) DE60212143T2 (enExample)
DK (1) DK1414487T3 (enExample)
ES (1) ES2271216T3 (enExample)
WO (1) WO2003013569A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60212143T2 (de) * 2001-07-27 2007-04-12 Orthologic Corp., Tempe Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera
EP1539214A4 (en) * 2002-07-02 2008-01-02 Orthologic Corp Thrombin
ATE362939T1 (de) * 2002-07-02 2007-06-15 Orthologic Corp Dimere von thrombinpeptidderivaten
PL1559431T3 (pl) 2003-12-31 2007-10-31 Orthologic Corp Kompozycja farmaceutyczna dla pochodnych peptydu trombiny
WO2007035406A1 (en) * 2005-09-16 2007-03-29 Orthologic Corp. Antibodies to complementary peptides of thrombin or portions thereof
EP2155234A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for chronic dermal ulcers
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
CA2719940A1 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
AU2009229395A1 (en) * 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
EP2538874A4 (en) * 2010-02-24 2017-06-21 Syneron Medical Ltd. A body contouring apparatus
US8806615B2 (en) 2010-11-04 2014-08-12 Mcafee, Inc. System and method for protecting specified data combinations
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049309A2 (en) * 1999-12-29 2001-07-12 Pfizer Limited Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
WO2002044413A2 (en) * 2000-12-01 2002-06-06 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
WO1996040033A1 (en) 1995-06-07 1996-12-19 Clarion Pharmaceuticals Inc. Non-biological patch for hemostasis
DE60212143T2 (de) * 2001-07-27 2007-04-12 Orthologic Corp., Tempe Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049309A2 (en) * 1999-12-29 2001-07-12 Pfizer Limited Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue
WO2002044413A2 (en) * 2000-12-01 2002-06-06 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
acceleration of full-thickness wound healing in normalratsbythe synthetic thrombin peptide,TP508. Stiernberg J 等.wound repair and regeneration,Vol.8 No.3. 2000 *

Also Published As

Publication number Publication date
US7833982B2 (en) 2010-11-16
CA2455756A1 (en) 2003-02-20
US20040209819A1 (en) 2004-10-21
DE60212143T2 (de) 2007-04-12
HK1065719A1 (en) 2005-03-24
US7378500B2 (en) 2008-05-27
CA2455756C (en) 2013-04-02
AU2002236768B2 (en) 2006-06-08
JP4192093B2 (ja) 2008-12-03
WO2003013569A3 (en) 2003-12-11
EP1414487A2 (en) 2004-05-06
US20090029923A1 (en) 2009-01-29
CN1556711A (zh) 2004-12-22
DK1414487T3 (da) 2006-10-09
US20060241049A1 (en) 2006-10-26
EP1414487B1 (en) 2006-06-07
WO2003013569A2 (en) 2003-02-20
DE60212143D1 (de) 2006-07-20
ATE328606T1 (de) 2006-06-15
JP2004538320A (ja) 2004-12-24
US7049294B2 (en) 2006-05-23
ES2271216T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
US7833982B2 (en) Methods of treating dermal ulcers with thrombin derived peptides
JP3150338B2 (ja) プロテアーゼ ネキシン―ｉの創傷治▲ゆ▼を仲介することへの使用
JP6703040B2 (ja) 角膜創傷治癒および眼表面疾患のためのヒスタチン
KR101514414B1 (ko) 당뇨병성 족부 궤양의 치료방법
KR20010041408A (ko) 상처 치유용 매트릭스 단백질 조성물
JP2025125558A (ja) 皮膚科障害の処置のための薬剤
AU2002236768A1 (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
JPH04211019A (ja) 創傷治癒促進のためのトロンボスポンデインの使用
KR20080031405A (ko) 상피 재생의 촉진
JP4351041B2 (ja) 傷治癒のための処置および組成物
JP4668612B2 (ja) トロンビンペプチド誘導体ダイマー
JP2006514822A (ja) トロンビンペプチド誘導体
US12214024B2 (en) Use of APC analogue for wound healing
HK1065719B (en) Use of thrombin-derived peptides for the therapy of chronic dermal ulcers
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
Rao et al. Recombinant human epidermal growth factor in healing of pressure ulcers
HK40047629A (zh) 皮肤病治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: OSOLUGIAIS CO., LTD.

Free format text: FORMER OWNER: THE BOARD OF REGENTS, THE UNIV. OF TEXAS SYSTEM

Effective date: 20051223

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051223

Address after: Arizona, USA

Applicant after: Orthologic Corp.

Address before: American Texas

Applicant before: Board of Regents of the Univ. of Texas System

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090708

Termination date: 20160116

EXPY Termination of patent right or utility model